Consistent with those in the FFD-induced MASH model, the serum levels and tissue expression of A1AT were notably decreased, whereas the PR3 levels and the PR3/A1AT ratio were increased in the serum samples from patients with MASLD/MASH (Fig. 1l, m). This evidence concerns the gene PRTN3 and metabolic dysfunction-associated steatotic liver disease.